Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay

@inproceedings{FernndezSalas2012BotulinumNS,
  title={Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay},
  author={Ester Fern{\'a}ndez-Salas and Joanne H. Wang and Yanira Molina and Jeremy B. Nelson and Birgitte P. S. Jacky and Kei Roger Aoki},
  booktitle={PloS one},
  year={2012}
}
Botulinum neurotoxin serotype A (BoNT/A), a potent therapeutic used to treat various disorders, inhibits vesicular neurotransmitter exocytosis by cleaving SNAP25. Development of cell-based potency assays (CBPAs) to assess the biological function of BoNT/A have been challenging because of its potency. CBPAs can evaluate the key steps of BoNT action: receptor binding, internalization-translocation, and catalytic activity; and therefore could replace the current mouse bioassay. Primary neurons… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
25 Citations
50 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Botulinum toxin: applying the 3Rs to product potency testing

  • D Sesardic, R Gaines Das
  • 2009
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…